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Research
AbstrACt
Objectives Ischaemic heart diseases (IHDs) are a leading 
cause of death worldwide. Although prescribing according 
to guidelines improves health outcomes, it remains 
suboptimal. We determined whether interventions targeted 
at healthcare professionals are effective to enhance 
prescribing and health outcomes in patients with IHDs.
Methods We systematically searched PubMed and 
EMBASE for studies published between 1 January 2000 
and 31 August 2017. We included original studies of 
interventions targeted at healthcare professionals to 
enhance prescribing guideline-recommended medications 
for IHDs. We only included randomised controlled trials 
(RCTs). Main outcomes were the proportion of eligible 
patients receiving guideline-recommended medications, 
the proportion of patients achieving target blood pressure 
and target low-density lipoprotein-cholesterol (LDL-C)/
cholesterol level and mortality rate. Meta-analyses 
were performed using the inverse-variance method 
and the random effects model. The quality of evidence 
was assessed using the Grading of Recommendations, 
Assessment, Development, and Evaluation approach.
results We included 13 studies, 4 RCTs (1869 patients) 
and 9 cluster RCTs (15 224 patients). 11 out of 13 
studies were performed in North America and Europe. 
Interventions were of organisational or professional nature. 
The interventions significantly enhanced prescribing 
of statins/lipid-lowering agents (OR 1.23; 95% CI 1.07 
to 1.42, P=0.004), but not other medications (aspirin/
antiplatelet agents, beta-blockers, ACE inhibitors/
angiotensin II receptor blockers and the composite 
of medications). There was no significant association 
between the interventions and improved health outcomes 
(target LDL-C and mortality) except for target blood 
pressure (OR 1.46; 95% CI 1.11 to 1.93; P=0.008). The 
evidence was of moderate or high quality for all outcomes.
Conclusions Organisational and professional 
interventions improved prescribing of statins/lipid-lowering 
agents and target blood pressure in patients with IHDs but 
there was little evidence of change in other outcomes.
PrOsPErO registration number CRD42016039188.
IntrOduCtIOn
Ischaemic heart diseases (IHDs) are a leading 
cause of death worldwide accounting for 
13.2% of all deaths globally.1 IHDs include 
angina pectoris and myocardial infarction.2 
International guidelines recommend using 
a combination of an antiplatelet agent, a 
beta-blocker, an ACE inhibitor or an angio-
tensin II receptor blocker (ACEI/ARB) 
and an HMG coenzyme A reductase inhib-
itor (statin) to treat eligible patients with 
IHDs.3–8 This combination is an effective 
secondary prevention after myocardial infarc-
tion, reducing morbidity and mortality.9–13 
Despite such evidence, rates of patients 
being prescribed medications according to 
guidelines varied from <5.0% to >95.0%, 
strengths and limitations of this study
 ► This is a systematic review and meta-analysis of 
randomised controlled trials, conducted following 
the Cochrane Handbook for Systematic Reviews of 
Interventions and the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses statement.
 ► This review focused on interventions targeted at 
healthcare professionals to enhance prescribing of 
individual medications for acute coronary syndrome. 
Interventions were classified according to the 
Cochrane Effective Practice and Organization of 
Care Review Group. But more detailed analyses, 
for example, on duration or intensity of intervention 
implementation, were impossible due to the limited 
number of studies.
 ► We may have missed relevant unpublished or locally 
published studies as we restricted our search to 
English publications and did not search for grey 
literature.
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leaving a substantial proportion of patients with IHDs not 
receiving guideline-recommended care.14–17 Changing 
clinicians’ behaviour to improve prescribing guide-
line-recommended medications is challenging. Different 
types of interventions have been developed and classi-
fied as professional interventions (eg, education,18–21 
reminders,22 audit and feedback23), organisational inter-
ventions (eg, computerised clinical guidelines,24 phar-
macist-led intervention25), financial interventions (eg, 
financial incentives26) and regulatory interventions (eg, 
cap and copayment policies27).
Interventions to improve prescribing guideline-rec-
ommended medications for cardiovascular diseases, 
in general, have been reviewed recently.28 29 Moreover, 
Murphy et al have evaluated the effect of organisational 
interventions for patients with IHDs.30 The interventions 
aimed to improve mortality and hospital admissions and 
targeted physicians and patients to adhere to recommen-
dations of secondary prevention of IHDs (lifestyle modi-
fication, prescribing medications or both).30 No work has 
been done synthesising the evidence on interventions to 
enhance prescribing according to guidelines for patients 
with IHDs as far as we are aware. In this review, we focus 
on interventions targeted at health professionals. Other 
factors influencing prescribing, such as patient behaviour, 
organisational factors or resource constraints are outside 
the scope of this review.31 We conducted a systematic 
review and meta-analysis to determine whether interven-
tions targeted at healthcare professionals are effective 
to enhance prescribing and health outcomes in patients 
with IHDs.
MEthOds
We conducted a systematic review and meta-analysis 
in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses Statement32 and 
the Cochrane Handbook for Systematic Reviews of Inter-
ventions.33 We registered our protocol with the Interna-
tional Prospective Register of Systematic Reviews Registry 
(CRD42016039188).34
We searched the electronic bibliographic databases 
PubMed and EMBASE as these are considered to be the 
most important sources for reports of trials.33 The search 
strategy included MeSH terms and relevant keywords in 
various combinations relating to guidelines, guideline 
adherence, drug therapy, IHDs and randomised trials 
(see online supplementary appendix A). We restricted 
our search to studies carried out in humans and published 
in English. Studies published between 1 January 2000 and 
31 August 2017 were sought. References of included arti-
cles were manually screened to identify additional eligible 
studies.
We included original studies reporting results 
of randomised controlled trials (RCTs) or cluster 
randomised  controlled trials (cluster RCTs) in patients 
with IHDs eligible for receiving secondary preventive 
treatment. Studies had to evaluate interventions targeted 
at healthcare professionals to enhance prescribing of 
guideline-recommended medications. The trials had to 
include at least one prospectively assigned concurrent 
control group. The control group had to receive usual 
care (not receiving the intervention), or an intervention 
of lower intensity or shorter duration than the interven-
tion group. Studies had to report patient-level outcomes. 
We excluded duplicate reports, post hoc analyses or 
abstracts from meeting proceedings unless published as 
full-text reports in a peer-reviewed journal. We excluded 
studies on patients receiving acute treatment in hospital 
only; or interventions predominantly targeting patient 
medication-taking behaviour or lifestyle modifications.
All titles and abstracts retrieved from the electronic 
searches were archived in the web-based bibliography and 
database manager RefWorks. After removing duplicates, 
two reviewers (TN and HQN) independently screened 
the titles and abstracts. They also independently assessed 
the full text of potentially eligible studies. Disagreements 
between the reviewers whether to include or exclude a 
study were resolved by consensus.
Two reviewers (TN and NNW) independently extracted 
data from the trials’ primary texts, the online supplemen-
tary appendices and protocols using a data abstraction 
form. We extracted the following information: trial name, 
year of publication, sources of funding, setting and time 
of recruitment, study design, study population character-
istics, details of the intervention and control conditions, 
main outcomes and evidence for assessment of the risk 
of bias. Disagreements were resolved by discussion with a 
third reviewer (KT).
Two reviewers (TN and NNW) independently assessed 
the risk of bias of each study using the tool of the Cochrane 
Effective Practice and Organization of Care Review Group 
(EPOC).35 The nine standard criteria were: (1) random 
sequence generation, (2) allocation sequence conceal-
ment, (3) similarity of baseline outcome measures, (4) 
similarity of baseline characteristics, (5) blinding of 
outcome assessment, (6) adequately addressing incom-
plete outcome data, (7) adequate protection against 
contamination, (8) free from selective reporting and 
(9) free from other risks of bias (eg, recruitment bias 
or not adjusting for clustering effect in cluster RCTs).35 
Disagreements were resolved by discussion with a third 
reviewer (KT). We judged trials with four or more high-
risk domains, or three or more high-risk domains plus 
three or more unknown domains as having a high risk 
of bias.
The primary outcomes were the proportion of eligible 
patients receiving the following guideline-recommended 
medications: aspirin/antiplatelet agents, beta-blockers, 
ACEIs/ARBs, statins/lipid-lowering agents and a 
composite of these medications. The secondary outcomes 
were: the proportion of eligible patients achieving target 
blood pressure and target LDL-C/cholesterol level, and 
the mortality rate.
The interventions were classified according to the 
taxonomy of the EPOC36 as professional, financial, 
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organisational or regulatory interventions. We performed 
meta-analyses for outcomes when the necessary data were 
available. Meta-analyses were performed in the Review 
Manager V.5.3 (RevMan 5)37 using the inverse-vari-
ance method and the random effects model. The main 
outcomes were measured as dichotomous variables. The 
OR with corresponding 95% CI was calculated for each 
outcome of interest to generate a forest plot. For studies 
with more than two trial groups, we combined relevant 
groups to create a single pair-wise comparison.33 A Z-test 
was used to assess the statistical significance of the results 
of the meta-analysis with a two-tailed P value of <0.05. The 
intracluster correlation coefficients (ICCs) for cluster 
RCTs were used to calculate the effective sample size to 
ensure the clustering effect was taken into account in our 
analyses. When an ICC was not reported in a cluster RCT, 
we contacted the trial authors. In case of non-response, 
we used the mean of corresponding ICCs reported in the 
other included cluster RCTs to adjust for the clustering 
effect.38 39
Two reviewers (KT and TN) independently assessed 
the quality of evidence across included studies of all 
outcomes of interest using the Grading of Recommenda-
tion, Assessment, Development, and Evaluation (GRADE) 
approach.40 The following criteria were used: serious 
limitations in study design and implementation, indirect-
ness, substantial heterogeneity, imprecision and publica-
tion bias. The GRADE approach specifies four levels of 
quality: high, moderate, low and very low. The quality 
rating was downgraded by one level for each factor having 
a serious limitation, up to a maximum of three levels for 
all factors. Heterogeneity across trials for each outcome 
of interest was investigated using the Cochran's Q test and 
was measured by the I2 statistic. An I2 exceeding 50% indi-
cated substantial statistical heterogeneity.33 41 Publication 
bias was evaluated visually by inspecting funnel plots and 
quantified by the Egger's test for outcomes comprising at 
least 10 trials.33 42
We performed subgroup analyses and sensitivity anal-
yses when the necessary data were available. Subgroup 
analyses were performed for type of study designs, type 
of intervention, comparators and setting of the interven-
tion. We examined the robustness of our findings in sensi-
tivity analyses excluding studies with high overall risk of 
bias, and analyses without adjusting for clustering effect.33
rEsults
The search of PubMed and EMBASE databases provided 
a total of 8424 citations, and 452 citations were added 
from the lists of references from included studies. After 
removing duplicates, 7535 remained. Of those, 7219 
papers were discarded after screening titles and abstracts. 
The full text of 316 studies was examined in more detail, 
303 studies did not meet the inclusion criteria. A total of 
13 studies43–59 were identified for inclusion in the review 
(figure 1). These were 4 RCTs45 49 51 59 involving 1869 
patients and 9 cluster RCTs43 47 50 52 53 55–58 involving 599 
healthcare centres and 15 224 patients. Trials were carried 
out between 1997 and 2012 and published between 2001 
and 2015. Control groups received usual care (nine 
studies43 45 49–52 55 58 59) or less intensive interventions (four 
studies47 53 56 57). Seven studies43 49 52 53 55 57 59 reported 
patients’ health outcomes (table 1). The overall risk of 
bias was rated as low in all included studies (table 1 and 
more details in online supplementary appendix B).
Five studies45 49 50 52 59 used organisational interven-
tions, four studies51 53 55 58 professional interventions and 
four studies43 47 56 57 a combination of organisational and 
professional interventions. Distribution of educational 
materials, educational outreach visits, audit and feedback 
and reminders were the four professional interventions 
most frequently used. Continuity of care, communica-
tion and case discussions between distant healthcare 
professionals were the two organisational interventions 
most frequently used (table 2 and more details in online 
supplementary appendix C).
Interventions had no significant effect on prescribing 
guideline-recommended medications, that is, there was 
no significant difference in the proportion of eligible 
patients receiving guideline-recommended medica-
tions between intervention and control groups except 
for statins/lipid-lowering agents. The findings were 
aspirin/antiplatelet agents (OR 1.13; 95% CI0.87 to 1.47; 
P=0.360), beta-blockers (OR 1.13; 95% CI 0.93 to 1.37; 
P=0.230), ACEIs/ARBs (OR 1.04; 95% CI 0.88 to 1.23; 
P=0.620) and statins/lipid-lowering agents (OR 1.23; 
95% CI 1.07 to 1.42; P=0.004), the composite of medi-
cations (OR 1.07; 95% CI 0.73 to 1.58; P=0.720). The 
evidence was of moderate or high quality for the primary 
outcomes (figure 2 and table 3).
Figure 1 Flow chart diagram of study selection.
group.bmj.com on January 12, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
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Figure 2 Primary outcomes of intervention vs control. ACEI, ACE inhibitors; ARB, angiotensin II receptor blocker. 
group.bmj.com on January 12, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
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The interventions significantly increased the propor-
tion of patients achieving target blood pressure (OR 1.46; 
95% CI 1.11 to 1.93; P=0.008), but there was no signifi-
cant difference in the proportion of patients achieving 
target LDL-C/cholesterol (OR 1.05; 95% CI 0.90 to 1.22; 
P=0.550), and in mortality rate (OR 0.78; 95% CI 0.48 to 
1.27; P=0.320) between intervention and control groups. 
The evidence was of moderate quality for the secondary 
outcomes (figure 3 and table 3).
No substantial statistical heterogeneity was detected 
in our study outcomes (all eight I2 values were <50%) 
(figure 2 and figure 3). The publication bias was rated as 
no risk (in aspirin/antiplatelet agents, beta-blockers and 
statins/lipid-lowering agents) and unknown risk (in the 
other outcomes) (see online supplementary appendix 
D). In subgroup analyses, there was no significant differ-
ence in the effect of the interventions on prescribing 
guideline-recommended medications and patients’ 
health outcomes between subgroups with all P values 
for the interaction of >0.05. No subgroup analysis could 
be done for the composite of medications and mortality 
rate as there were only two studies available for each of 
these outcomes (see online supplementary appendix E). 
We did not perform sensitivity analyses excluding studies 
with high overall risk of bias because all included studies 
were rated as low risk. The findings of all outcomes did 
not change in sensitivity analyses when not adjusting for 
clustering effects (see online supplementary appendix F).
dIsCussIOn
Interventions to enhance prescribing guideline-rec-
ommended medications for patients with IHDs were of 
organisational or professional nature. The interventions 
Figure 3 Secondary outcomes of intervention vs control. LDL-C, low-density lipoprotein-cholesterol. 
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significantly enhanced prescribing of statins/lipid-low-
ering agents, but not other medications. There was no 
significant association between the interventions and 
improved health outcomes, except for target blood pres-
sure. The evidence was of moderate or high quality for all 
outcomes.
Why did the interventions not improve prescribing 
of most medications? The high baseline performance, 
especially of antiplatelet agents, might limit the scope for 
further improvement.45 47 49 50 53 59 The baseline measures 
were better than expected which may indicate ‘a rising tide 
phenomenon’, a metaphor for a secular upward trend, 
being a possible explanation of null results.60 In addition, 
an increased awareness of treatment recommendations 
derived from efforts by local organisations and reports docu-
menting poor compliance with recommendations could 
contribute to this phenomenon.50 60 The Hawthorne effect 
may also explain the results. Extra attention by researchers 
and higher levels of clinical surveillance, equally present in 
treatment and control groups, may over-estimate response 
in both groups.61 As a consequence, the control groups 
improved their performance alongside the intervention 
groups in included studies.52 53 55–58 Furthermore, many 
other factors impact on prescribing including patients 
and resource constraints which were not assessed in the 
studies.31
What are possible explanations for finding effects on 
prescribing statins/lipid-lowering agents? First, there were 
more patients eligible for receiving statins/lipid-lowering 
agents than antihypertensive agents (beta-blockers or 
ACEIs/ARBs). Furthermore, statins/lipid-lowering agents 
are recommended to be prescribed for all patients with 
IHDs, regardless of their LDL-C level.3–8 Physicians tend to 
be more careful when prescribing beta-blockers because of 
concerns about their side effects.62 Physicians also possibly 
favoured other classes of medications to monitor patients’ 
blood pressure level and survival (eg, calcium channel 
inhibitors).62 It was surprising that the interventions had an 
impact on prescribing of statins/lipid-lowering agents, but 
not on LDL-C/cholesterol level. In contrast, interventions 
did not have an impact on prescribing antihypertensive 
agents, but target blood pressure improved. Whether or 
not adequate dosing had been achieved was not measured 
in the trials, but this has an effect on patients’ outcomes. 
For example, the benefits of more intensive therapy with 
statins have been established.63 Lack of patient adherence 
with medication could also be an explanation, but this was 
not measured in the trials. Patient adherence is reported to 
be better with antihypertensive agents than with statins.64 
In addition, lifestyle modifications65 66 also contribute 
to patients’ clinical outcomes and may have played an 
important role in improving blood pressure control. More 
work is needed to disentangle the associations. In partic-
ular, because our analyses for blood pressure and LDL-C/
cholesterol levels were based on a few studies only.
Our findings are consistent with previous systematic 
reviews28 29 reporting professional and organisational as 
the two main types of interventions to improve healthcare 
professionals' adherence to cardiovascular disease guide-
lines. Our study and a systematic review by Jeffery et al28 
showed only some significant improvements. A system-
atic review by Unverzagt et al,29 in contrast, showed that a 
provider reminder system, audit and feedback, provider 
education or organisational change were effective inter-
ventions. However, results are difficult to compare as we 
measured different outcomes. We analysed the improve-
ment of prescribing for each medication separately while 
both review articles28 29 took all medication together. More-
over, we focused on patients with IHDs, whereas previous 
reviews28 29 included different cardiovascular diseases. 
Although programmes promoting guidelines such as the 
Guidelines Applied in Practice and Get With The Guide-
lines programmes also involving organisational and profes-
sional interventions demonstrated that it was possible to 
improve quality of care,67 the design of RCT is needed to 
confirm the improvement.
Several issues need to be addressed in our study. First, 
there were seven studies rated as having a high risk of other 
bias. Of these studies, six cluster RCTs50 52 53 56–58 had a high 
risk of recruitment bias. In those studies, patients were 
recruited after the clusters had been randomised and there-
fore, the knowledge of whether a cluster belonged to the 
intervention or control group could have affected patient 
recruitment. Farrin et al68 showed this in a trial of low 
back pain randomised by primary care practice; a greater 
number of less severe participants were recruited to the 
‘active management’ practices. However, we did not find 
significant differences in outcomes between RCTs45 49 51 59 
and cluster RCTs.43 47 50 52 53 55–58 Second, there were some 
cluster RCTs47 50 53 56 58 which did not report the ICCs. We 
used the mean ICCs for corresponding outcomes reported 
in the other included studies.39 The sensitivity analyses 
without adjusting for clustering effects showed similar 
results. The heterogeneity became substantial for the 
outcomes of aspirin/antiplatelet agents, the composite of 
medications and target LDL-C/cholesterol. But overall, the 
sensitivity analyses confirmed the robustness of our find-
ings. Third, we included studies of all types of interventions 
targeted at healthcare professionals in the meta-analyses. 
Subgroup analyses showed that there was no significant 
difference between subgroups of interventions (profes-
sional, organisational and professional plus organisational). 
But more detailed analyses, for example, on duration or 
intensity of the intervention, were impossible due to the 
limited number of studies. The length of patient follow-up 
varied across studies. This issue might increase the clinical 
heterogeneity of outcomes measured. Fourth, we included 
studies reporting patient-level outcomes, and excluded 
studies only reporting cluster-level outcomes (eg, hospital 
and practice performance scores).69 70 Fifth, we performed 
multiple statistical tests which increased the risk of type I 
error. Adjustment for multiple testing is debatable.71 In our 
study, three out of four primary outcomes were not signif-
icant, P value threshold adjustment would be too conser-
vative. Finally, our review included only studies published 
in English and we did not search for grey literature. So we 
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may have missed relevant unpublished or locally published 
studies.
Our results have several implications for practice and 
research. Eleven out of 13 studies come from North 
America and Europe, which limits the generalisability of 
our results to the rest of the world. There maybe a need 
to develop new interventions, especially for low-income 
and middle-income countries which have a rising burden 
of ischaemic heart diseases. There are some types of inter-
ventions such as financial and regulatory that have not 
been tested in this group.26 27 72 Selecting an intervention 
to enhance prescribing according to guidelines should be 
based on the local context. Interventions need to consider 
a range of barriers to change prescribing, including 
barriers related to patients, organisation of the healthcare 
system and resource constraints.31 Finally, improving guide-
line adherence may include strategies for improving clini-
cians’ awareness, agreement and adoption of guidelines. 
The cost-effectiveness of such interventions should also be 
evaluated.73–77
COnClusIOns
In conclusion, a number of organisational and professional 
interventions improved prescribing of statins/lipid-low-
ering agents and target blood pressure in patients with 
IHDs, but there was little evidence of change in other 
outcomes.
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